• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis
Conclusions: We demonstrate distinct changes in intrathecal B-cell homeostasis in patients with pedMS during active disease, which differ from those in adults by an expansion of plasmablasts in blood and CSF and similarly occur in prototypic autoantibody-driven autoimmune disorders. This emphasizes the particular importance of activated B-lymphocyte subsets for disease progression in the earliest clinical stages of MS.
Source: Neurology Neuroimmunology and Neuroinflammation - December 14, 2016 Category: Neurology Authors: Schwarz, A., Balint, B., Korporal-Kuhnke, M., Jarius, S., von Engelhardt, K., Fürwentsches, A., Bussmann, C., Ebinger, F., Wildemann, B., Haas, J. Tags: All Pediatric, Cerebrospinal Fluid, Multiple sclerosis Article Source Type: research

Sensitivity of Visual Evoked potentials and Spectral Domain Optical Coherence Tomography in Early Relapsing Remitting Multiple Sclerosis
Conclusions We have found higher prevalence of VEP abnormalities than SCOCT in early relapsing-remitting multiple sclerosis. This suggests that VEP has a higher sensitivity for detecting lesions of the visual pathway in patients with early RRMS.
Source: Multiple Sclerosis and Related Disorders - December 22, 2016 Category: Neurology Source Type: research

Multiple sclerosis among Afghan immigrants in Isfahan, Iran
Conclusion This study shows a lower prevalence of MS among Afghan residents of Isfahan compared to the overall prevalence of the province. Our result could be implying a stronger bond between genetic factors and developing MS, rather than the environmental factors.
Source: Multiple Sclerosis and Related Disorders - February 7, 2017 Category: Neurology Source Type: research

Incidence of Multiple Sclerosis in the Republic of Ireland: a prospective population-based study
Conclusions This is the first study to prospectively assess the incidence rate of MS in Ireland and shows that Ireland has a high incidence rate, comparable with the rest of the British Isles, with a persistent North-South gradient. The age of onset of relapsing remitting multiple sclerosis appears to be increasing over the last 20 years. It will be of interest to re-assess this population over time to see if increasing incidence rates, as well as improved survival, are driving the reported increases in MS prevalence.
Source: Multiple Sclerosis and Related Disorders - February 14, 2017 Category: Neurology Source Type: research

Upper Limb Impairment is Associated with Use of Assistive Devices and Unemployment in Multiple Sclerosis
Conclusions Upper limb impairment is common in older MS patients, and adversely affects the ability to perform many common daily activities.
Source: Multiple Sclerosis and Related Disorders - February 20, 2017 Category: Neurology Source Type: research

Study Links Multiple Sclerosis to Dementia Risk
It’s MS Awareness Week in the United States — the time of year that the National Multiple Sclerosis Society and people living with MS try to spread awareness of this disease. For the past several years, I’ve determined to spend this week educating people who live with MS about the disease they have. For past MS awareness weeks, I’ve written pieces on MS history and about the first recorded cases of MS. Today I write about research suggesting what might be in some of our futures. It’s not a happy topic, but I believe that forewarned is forearmed. A recent study published in the Journal of Epidemiology &...
Source: Life with MS - March 7, 2017 Category: Neurology Authors: Trevis Gleason Tags: multiple sclerosis awareness life with MS Living with MS MS and family MS symptoms trevis gleason Source Type: blogs

Multiple Sclerosis: Not a Win-or-Lose Game
I’ve often said that living with multiple sclerosis (MS) isn’t a death sentence — it’s a life sentence. What I mean by that is that (in most cases) we quite literally don’t die from multiple sclerosis, we die with MS. We are sentenced to a life of living with this disease, and that means trying to find a way over, under, around, or through the mountains that are dropped in our paths. Different Games, Different Ranking Systems Maybe it’s because of two sporting events that converged this weekend, but I’m beginning to think of this “living with MS” thing another way as well. The NCAA basketball tourna...
Source: Life with MS - April 4, 2017 Category: Neurology Authors: Trevis Gleason Tags: multiple sclerosis Source Type: blogs

Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis (P1.349)
Conclusions:Rates of non-adherence varied by information source. Better parent-reported physical functioning was the strongest predictor of adherence. Parental involvement in adherence was associated with worse PedQL-school functioning and lower MS-Self-Efficacy measured confidence in controlling MS.Study Supported by: National MS Society (HC0148)Disclosure: Dr. Schwarz has nothing to disclose. Dr. Grover has nothing to disclose. Dr. Powell has nothing to disclose. Dr. Noguera has nothing to disclose. Dr. Mah has received research support from Biogen, Sanofi-Genzyme, and Novartis. Dr. Mar has nothing to disclose. Dr. Medni...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Schwarz, C., Grover, S., Powell, V., Noguera, A., Mah, J., Mar, S., Mednick, L., Banwell, B., Alper, G., Graves, J., Lotze, T., Tillema, J.-M., Rensel, M., Gorman, M., Ness, J., Waldman, A., Schreiner, T., Waubant, E., Yeh, E. A. Tags: Pediatric Multiple Sclerosis Source Type: research

Baseline characteristics and cytokine profiles across demographic subsets in the Intermountain Multiple Sclerosis Project (P1.382)
Conclusions:Our study presents further analysis of a large MS cohort for differences in cytokine concentrations compared to controls. Analysis of demographic subsets was notable for a shift to anti-inflammatory cytokines with age. The underlying immunology and potential implications of these results will be discussed.Disclosure: Dr. Baldassari has nothing to disclose. Dr. Seraj has nothing to disclose. Dr. Husebye has nothing to disclose. Dr. Paz Soldan has nothing to disclose. Dr. Martins has nothing to disclose. Dr. Carlson has received research support from Biogen. Dr. Rose has received research support from Biogen Idec...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Baldassari, L., Seraj, H., Husebye, D., Soldan, M. P., Martins, T., Carlson, N., Rose, J. Tags: Biomarkers and Experimental Studies for Multiple Sclerosis I Source Type: research

Chronic comorbidity in multiple sclerosis is associated with dissolved intimate relationships (P3.331)
Conclusions:These results indicate that comorbidity increases the relationship distress in persons with MS, further adding to the list of marginalization induced by the concomitant presence of other chronic disease with MS. Our results underscore the burden of comorbidity in MS on patients, their partners, families and society.Study Supported by: The Danish Multiple Sclerosis Society and Foundation for Research in Neurology.Disclosure: Dr. Thormann has received personal compensation for activities with Novartis and Teva as a scientific advisory board member or speaker. Dr. Sorensen has received personal compensation from B...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Thormann, A., Sorensen, P. S., Koch-Henriksen, N., Thygesen, L. C., Laursen, B., Magyari, M. Tags: Quality of Life, Symptoms and Symptomatic Therapy, Comorbidity, and Patient Reported Outcomes in Multiple Sclerosis Source Type: research

The impact of the Syrian war on Multiple Sclerosis (MS) patients (P3.338)
Conclusions:Prevalence of MS has increased in Syria despite the decreased incidence during the last 5 years. Survival rates has also declined dramatically. These findings are due to limited accessibility to medical resources. As a result, many MS patients remain undiagnosed and patients who are diagnosed are less likely to surviveDisclosure: Dr. Almallouhi has nothing to disclose. Dr. Almallouhi has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Almallouhi, E., Almallouhi, M. Tags: Quality of Life, Symptoms and Symptomatic Therapy, Comorbidity, and Patient Reported Outcomes in Multiple Sclerosis Source Type: research

Effects of Methylphenidate on Mobility, Cognition and Fatigue in Multiple Sclerosis: A Pilot Randomized Controlled Trial (P3.341)
Conclusions:Although limited by small sample size, this study suggests that methylphenidate up to 30mg bid is likely less effective than placebo for improving mobility, cognition or fatigue in MS.Study Supported by: National Multiple Sclerosis SocietyDisclosure: Dr. Cameron has received personal compensation for activities with ReWalk and Adamas as a consultant.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cameron, M. Tags: Quality of Life, Symptoms and Symptomatic Therapy, Comorbidity, and Patient Reported Outcomes in Multiple Sclerosis Source Type: research

Prevalence of Epilepsy and the Demographics, Clinical and Paraclinical Features in Patients with Multiple Sclerosis (P3.360)
Conclusions:Prevalence of epileptic seizure is increased in our MS database similar to other reports. About half of our patients had first onset seizure when in progressive disease stage and without an identifiable new MS plaques which suggest possible network failure or subclinical grey matter lesions as mechanisms of epileptic activity.Disclosure: Dr. Baharnoori has nothing to disclose. Dr. Stankiewicz has received personal compensation for activities with Teva Neuroscience, Novartis, Sanofi Genzyme, Biogen Idec, Genentech, and Bayer as a consultant. Dr. Chitnis received personal compensation for activities with Roche-Ge...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Baharnoori, M., Stankiewicz, J., Chitnis, T. Tags: Quality of Life, Symptoms and Symptomatic Therapy, Comorbidity, and Patient Reported Outcomes in Multiple Sclerosis Source Type: research

Exploratory Factor Analysis of a Patient-Reported Outcome Measure in a Multiple Sclerosis Population Cohort at a Large Academic Center (P3.365)
Conclusions:These findings support the utility of the Neuro-QoL in evaluating patient-reported outcomes in multiple sclerosis. However, not all original measure items accounted for sufficient variance in the factor analysis. Critical items for each factor are discussed.Disclosure: Dr. Medina has nothing to disclose. Dr. Valdez has nothing to disclose. Dr. Alvarez has received personal compensation from Teva Neuroscience, Biogen, Genzyme, Genentech, and Novartis. Dr. Alvarez has received research support from Biogen, Teva, and Novartis. Dr. Nair has received personal compensation for activities with Astellas. Dr. Nair has r...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Medina, L., Valdez, B., Alvarez, E., Nair, K. Tags: Quality of Life, Symptoms and Symptomatic Therapy, Comorbidity, and Patient Reported Outcomes in Multiple Sclerosis Source Type: research

Efficacy of Peripheral Lidocaine Application (Neural Therapy) in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients (P3.366)
Conclusions:These results suggest that NDO treatment in MS patients could be an effective treatment which is easy and has very few side effects, and is cost effective.Disclosure: Dr. Tamam has nothing to disclose. Dr. Ozdemir has nothing to disclose. Dr. Gedik has nothing to disclose. Dr. Tamam has nothing to disclose. Dr. Nazlikul has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Tamam, Y., Ozdemir, H. H., Gedik, A., Tamam, C., Nazlikul, H. Tags: Quality of Life, Symptoms and Symptomatic Therapy, Comorbidity, and Patient Reported Outcomes in Multiple Sclerosis Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20